NSGO-CTU/HERO
Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study
Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer
Studying the feasibility of collecting data on patient/carer satisfaction with end of life (EOL) care and of collecting details of that care in women with advanced gynaecological malignancies.
A phase II umbrella trial in patients with relapsed ovarian cancer.
Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Trial of Letrozole +/- Palbociclib in Metastatic Endometrial Cancer
ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.